论文部分内容阅读
目的:评估大肠癌患者血清MMP-7含量及其临床意义。方法:术前应用免疫酶联反应技术对50例大肠癌患者以及36例健康对照者的血清MMP-7含量进行检测,同时也检测这些患者血清CEA、CA19-9以及CA24-2含量。将大肠癌患者的血清MMP-7及其它肿瘤标志物的含量与健康对照者进行了比较。对不同临床病理分期的大肠癌患者血清MMP-7含量进行评估。结果:研究发现多数大肠癌患者的血清MMP-7含量升高。大肠癌患者的血清MMP-7含量,分布范围0.72-28.69ng/ml(平均4.41ng/ml;中位4.19ng/ml),显著高于健康对照者,分布范围0.69-3.97ng/ml(平均1.62ng/ml;中位1.36ng/ml)(P<0.01)。大肠癌患者的血清MMP-7平均阳性率(46%)与CEA(30%),CA19-9(26%)及CA24-2(24%)相比均升高(P<0.05)。进展期肿瘤患者血清MMP-7含量显著高于早期肿瘤患者(P<0.05)。结论:血清MMP-7有可能成为大肠癌患者临床监测标志物。
Objective: To evaluate the serum level of MMP-7 in patients with colorectal cancer and its clinical significance. Methods: The serum levels of MMP-7 in 50 patients with colorectal cancer and 36 healthy controls were detected by enzyme-linked immunosorbent assay (ELISA) before operation. Serum levels of CEA, CA19-9 and CA24-2 were also measured in these patients. The levels of serum MMP-7 and other tumor markers in patients with colorectal cancer were compared with those in healthy controls. Serum levels of MMP-7 in patients with different stages of colorectal cancer were evaluated. Results: The study found that most patients with colorectal cancer serum MMP-7 levels increased. Serum MMP-7 levels in patients with colorectal cancer ranged from 0.72 to 28.69 ng / ml (mean 4.41 ng / ml; median 4.19 ng / ml), significantly higher than those in healthy controls (range, 0.69-3.97 ng / ml 1.62 ng / ml; median 1.36 ng / ml) (P <0.01). The mean serum MMP-7 positive rate (46%) in patients with colorectal cancer was significantly higher than that in CEA (30%), CA19-9 (26%) and CA24-2 (24%) (P <0.05). The serum level of MMP-7 in advanced cancer patients was significantly higher than that in early cancer patients (P <0.05). Conclusion: Serum MMP-7 may become a clinical monitoring marker in patients with colorectal cancer.